119 related articles for article (PubMed ID: 8258968)
1. Lupus and its management.
Fagundus DM; Leroy EC
J S C Med Assoc; 1993 Nov; 89(11):516-24. PubMed ID: 8258968
[TBL] [Abstract][Full Text] [Related]
2. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Petri M; Jones RJ; Brodsky RA
Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis.
Felson DT; Anderson J
N Engl J Med; 1984 Dec; 311(24):1528-33. PubMed ID: 6390198
[TBL] [Abstract][Full Text] [Related]
4. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic drug treatment of lupus nephritis.
Donadio JV; Holley KE; Ilstrup DM
Am J Kidney Dis; 1982 Jul; 2(1 Suppl 1):178-81. PubMed ID: 7102666
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
7. [Intermittent intravenous cyclophosphamide application in patients with systemic lupus erythematosus].
Anić B; Crkvencić N; Mayer M; Bosnić D; Sentić M; Markeljević J; Cikes N
Lijec Vjesn; 1999; 121(9-10):283-8. PubMed ID: 19658369
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
[TBL] [Abstract][Full Text] [Related]
9. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
Arnal C; Piette JC; Léone J; Taillan B; Hachulla E; Roudot-Thoraval F; Papo T; Schaeffer A; Bierling P; Godeau B
J Rheumatol; 2002 Jan; 29(1):75-83. PubMed ID: 11824975
[TBL] [Abstract][Full Text] [Related]
10. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
McLaurin EY; Holliday SL; Williams P; Brey RL
Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
Holvast A; Huckriede A; Wilschut J; Horst G; De Vries JJ; Benne CA; Kallenberg CG; Bijl M
Ann Rheum Dis; 2006 Jul; 65(7):913-8. PubMed ID: 16322083
[TBL] [Abstract][Full Text] [Related]
12. Systemic Lupus Erythematosus: A Review.
Siegel CH; Sammaritano LR
JAMA; 2024 May; 331(17):1480-1491. PubMed ID: 38587826
[TBL] [Abstract][Full Text] [Related]
13. [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
Astudillo L; Sailler L; Carreiro M; Dahan S; Ollier S; Arlet P
Ann Med Interne (Paris); 2003 Feb; 154(1):3-6. PubMed ID: 12746653
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
15. [Aggressive therapy of highly active systemic lupus erythematosus].
Graninger W
Acta Med Austriaca; 1996; 23(4):129-33. PubMed ID: 9036724
[TBL] [Abstract][Full Text] [Related]
16. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
18. Lupus nephritis.
Sauter M; Anders HJ
Minerva Med; 2007 Dec; 98(6):749-58. PubMed ID: 18299686
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients.
Pattaragarn A; Sumboonnanonda A; Parichatikanond P; Supavekin S; Suntornpoch V; Vongjirad A
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S232-41. PubMed ID: 16856445
[TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus.
Manson JJ; Rahman A
Orphanet J Rare Dis; 2006 Mar; 1():6. PubMed ID: 16722594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
